
Solaris Resources Inc. (CVE:SLS – Free Report) – Stock analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Solaris Resources in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst H. Ihle now expects that the company will post earnings per share of ($0.19) for the year, up from their prior estimate of ($0.20).
Solaris Resources Stock Down 2.7%
Shares of SLS opened at C$6.15 on Friday. Solaris Resources has a 1 year low of C$1.38 and a 1 year high of C$7.09. The stock has a 50 day simple moving average of C$6.15 and a two-hundred day simple moving average of C$6.15.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
Featured Articles
- Five stocks we like better than Solaris Resources
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
